Inspire Medical Systems (INSP)
Health Care · Medical devices - neurostimulation · NYSE
Inspire Medical Systems manufactures implantable nerve stimulation devices that treat obstructive sleep apnea without surgery or continuous positive airway pressure (CPAP).
What Inspire Medical Systems does
Inspire Medical Systems develops and commercializes the Inspire system, an implantable neurostimulation device designed to treat obstructive sleep apnea by stimulating the hypoglossal nerve. The company generates revenue through device sales and implantation procedures. Inspire therapy is FDA-approved and reimbursed by major insurance providers. The company operates primarily in the United States and is expanding internationally.
Themes: ["obstructive sleep apnea treatment","implantable neurostimulation","sleep medicine","CPAP alternatives"]
Fundamentals
- Price$51.52 as of 2026-07-09 close
- Market cap$1.5B as of 2026-07-10
- 1-year return-63.1% as of 2026-07-09 close
- P/E11.26 as of 2026-07-10
- Net margin+14.3% as of 2026-07-10
- Gross margin+85.8% as of 2026-07-10
- ROE+18.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+8.9% as of 2026-07-10
- Revenue CAGR (3y)+30.8% SEC XBRL
- Beta0.66 as of 2026-07-10
Key risks (from latest filing)
["Heavy dependence on Inspire system as sole revenue source creates concentration risk","Reimbursement coverage and reimbursement rate changes by insurance providers could significantly impact revenue","Competition from established CPAP manufacturers and alternative sleep apnea treatments including emerging neurostimulation competitors"]
Competitors & peers
- ResMed (RMD)
- Philips Respironics
- ApnaMed
- Nyxoah
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.